Related Experiment Videos
Vigabatrin and lamotrigine in refractory epilepsy
I Stolarek1, J Blacklaw, G Forrest
1University Department of Medicine and Therapeutics, Western Infirmary, Glasgow, UK.
Journal of Neurology, Neurosurgery, and Psychiatry
|August 1, 1994
Summary
Adding lamotrigine (LTG) to vigabatrin (VIG) significantly improved seizure control in patients with refractory epilepsy. This combination therapy demonstrated substantial efficacy and minimal side effects, offering a promising approach for managing difficult-to-treat epilepsy cases.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Medicine
Background:
- Epilepsy is characterized by an imbalance between inhibitory and excitatory brain activity.
- Vigabatrin (VIG) enhances inhibitory neurotransmission by inhibiting gamma-aminobutyric acid breakdown.
- Lamotrigine (LTG) modulates excitatory neurotransmission by reducing amino acid release.
Purpose of the Study:
- To evaluate the efficacy and safety of adjunctive lamotrigine (LTG) in patients with refractory epilepsy already treated with vigabatrin (VIG).
- To assess the impact of LTG on seizure frequency and type in this patient population.
Main Methods:
- A balanced, double-blind, placebo-controlled, crossover trial involving 22 patients with refractory epilepsy.
- Patients received VIG plus escalating doses of LTG (25, 50, 100 mg twice daily for 4 weeks each) or placebo, followed by 4-week washout periods.
- Seizure counts, seizure types, and adverse events were monitored throughout the study.
Main Results:
- 14 out of 20 completers showed improvement, with significant reductions in seizure days and numbers.
- LTG demonstrated efficacy in partial and secondarily generalized tonic-clonic seizures.
- At 200 mg daily, LTG resulted in a median 37% fall in seizure count, with 45% of patients experiencing >50% reduction; 3 patients became seizure-free.
Conclusions:
- Adjunctive LTG in patients on VIG offers substantial efficacy for refractory epilepsy.
- Combining drugs with complementary mechanisms, like VIG and LTG, represents a rational strategy for managing refractory epilepsy.
- The combination therapy was well-tolerated with minimal side effects and did not alter levels of other antiepileptic drugs.